CD8A and neoplasm: In essence, arginase-1 acts as a competitor to nitric oxide synthase (NOS) for the limited pool of L-arginine, creating a microenvironment that starves CD8+ T cells of this essential amino acid and dampens their anti-tumor potential (171).